Outlook Therapeutics, Inc. (OTLK) Stock Price & Analysis
Outlook Therapeutics, Inc. (OTLK) fell 2.40% to USD 0.7 as of June 10, 2026 at 06:52 UTC, according to Nexqual real-time market data.
OTLK last closed at USD 0.72; the session ranged USD 0.68–0.75 on volume of 7,503,261 shares. Market capitalization is $104.71M, with a 52-week range of USD 0.16–3.39 (NCM). Source: Nexqual, June 10, 2026 at 06:52 UTC.
Key Statistics (as of June 10, 2026 at 06:52 UTC)
| Price | USD 0.7 |
|---|---|
| Change | ▼ 2.40% (down) |
| Previous Close | USD 0.72 |
| Open | USD 0.72 |
| Day Range | USD 0.68 – 0.75 |
| 52-Week Range | USD 0.16 – 3.39 |
| Volume | 7,503,261 shares |
| Market Cap | $104.71M |
| Exchange | NCM |
Technical Analysis (OTLK)
Nexqual's technical model rates OTLK "STRONG BUY" based on 5 bullish and 0 bearish signals across 123 daily candles, as of June 10, 2026 at 06:52 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 69.37 (neutral) |
| vs SMA50 | Above (USD 0.35) |
| MACD | 0.14 (positive) |
Analyst Ratings (OTLK)
Wall Street analysts rate OTLK "Buy" based on 3 analysts, with a mean price target of USD 4.17 (range USD 0.5–6), per Nexqual as of June 10, 2026 at 06:52 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 4.17 |
| High Target | USD 6 |
| Low Target | USD 0.5 |
| Buy / Hold / Sell | 2 / 2 / 0 |
Earnings (OTLK)
| Next Earnings Date | 2026-08-13 |
|---|---|
| EPS Estimate | USD -0.11 |
| Revenue Estimate | $500,000 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.17 vs est -0.12 ▼ miss |
| 2025-12-31 | USD -0.22 vs est -0.17 ▼ miss |
| 2025-09-30 | USD -0.29 vs est -0.25 ▼ miss |
| 2025-06-30 | USD -0.44 vs est -0.39 ▼ miss |
Source: Nexqual, June 10, 2026 at 06:52 UTC.
Financials & Fundamentals (OTLK)
| Total Revenue | $333,141 |
|---|---|
| Gross Margin | +0.00% |
| Operating Margin | -11006.82% |
| Profit Margin | +0.00% |
| Current Ratio | 0.54 |
| Total Cash | $7.75M |
| Total Debt | $27.19M |
| Free Cash Flow | $-25.47M |
Source: Nexqual, June 10, 2026 at 06:52 UTC.
Financial Health Score (OTLK)
Nexqual rates Outlook Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 06:52 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $8M cash vs $27M debt |
| Cash Flow | Weak — FCF negative: -$25M, burning cash |
| Efficiency | Mixed — No data |
Ownership (OTLK)
| Insider Ownership | +17.42% |
|---|---|
| Institutional Ownership | +6.92% |
| Shares Outstanding | 148.59M |
| Float | 96.40M |
| Short % of Float | +11.95% |
Source: Nexqual, June 10, 2026 at 06:52 UTC.
Leadership (OTLK)
Outlook Therapeutics, Inc. is led by Robert Charles Jahr (age 52), President, CEO & Director, per Nexqual as of June 10, 2026 at 06:52 UTC.
| President, CEO & Director | Robert Charles Jahr (age 52) |
|---|---|
| EVP, CFO, Treasurer, Secretary & Director | Lawrence A. Kenyon (age 59) |
| Senior Vice President of Licensing and M & A | Joel Prieve |
| Senior Vice President of Medical Affairs | Surendra Sharma |
| Senior Vice President of Clinical Development & Regulatory Affairs | Jennifer M. Kissner |
Major Backers & Investors (OTLK)
Notable institutional backers of Outlook Therapeutics, Inc. include Armistice Capital, LLC, Gilpin Wealth Management, LLC, Fidelity, according to Nexqual as of June 10, 2026 at 06:52 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Armistice Capital, LLC | 2.98% |
| Gilpin Wealth Management, LLC | 0.43% |
| Fidelity | 0.36% |
| Commonwealth Equity Services, LLC | 0.34% |
| Warberg Asset Management LLC | 0.2% |
| Renaissance Technologies | 0.18% |
| Nine Masts Capital Ltd. | 0.17% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.8% |
| BlackRock | 0.44% |
| Geode Capital | 0.43% |
Source: Nexqual, June 10, 2026 at 06:52 UTC.
From Outlook Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2025-12-19)
Key Strengths & Strategy (as disclosed to the SEC)
- Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications.
- Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
- Outlook Therapeutics, Inc. has collaboration agreements with Cencora.
- Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| VTGN | VistaGen Therapeutics, Inc. | USD 0.54 | ▼ 0.41% |
| VTVT | vTv Therapeutics Inc. | USD 31.77 | ▼ 1.15% |
| ITRMF | Iterum Therapeutics plc | USD 0.05 | ▲ 0% |
| DARE | Dare Bioscience, Inc. | USD 1.92 | ▲ 2.13% |
| CYPH | Cypherpunk Technologies Inc. | USD 0.68 | ▲ 30.17% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 06:52 UTC. This page is informational and not investment advice.